CURE grants cannabis leader rights to its proprietary drug delivery technology in markets around the world.

LOS ANGELES, Sept. 05, 2018 (GLOBE NEWSWIRE) — CURE Pharmaceutical (OTC:CURR), (“CURE”), an innovative drug delivery and development company, today announced that it entered into a multi-year licensing agreement for the first time with a leading international cannabis company. Under the terms of the agreement, the cannabis company will have an exclusive license to CURE’s patented, multi-layer oral thin film (OTF), CUREfilm